Reversible bilateral ototoxicity in a patient with chronic hepatitis B during peginterferon alpha-2a treatment

Peginterferon alpha-2a (PEG IFN α-2a) is frequently used in chronic hepatitis B (CHB)treatment. Numerous adverse events can be noted during this therapy such as flu-like disease, rash, weight loss and depression. However, PEG IFN α-2a related ototoxicity seems to be an uncommon entity. Ototoxicity c...

Descripción completa

Detalles Bibliográficos
Autores principales: Gozdas, Hasan Tahsin, Karabay, Oguz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Drug Watch
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4375807/
https://www.ncbi.nlm.nih.gov/pubmed/25821325
http://dx.doi.org/10.4103/0253-7613.150377
Descripción
Sumario:Peginterferon alpha-2a (PEG IFN α-2a) is frequently used in chronic hepatitis B (CHB)treatment. Numerous adverse events can be noted during this therapy such as flu-like disease, rash, weight loss and depression. However, PEG IFN α-2a related ototoxicity seems to be an uncommon entity. Ototoxicity can be detected objectively by audiometry. In this paper, we present a case of CHB who developed reversible bilateral ototoxicity during PEG IFN α-2a treatment. Due to ototoxicity detected objectively by audiogram, treatment was ceased at sixth month and ototoxicity completely recovered one month after stopping the drug.

Ejemplares similares